Jazz Pharmaceuticals plc
JAZZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $4 | $4 | $4 | $3 |
| % Growth | 6.1% | 4.8% | 18.3% | – |
| Cost of Goods Sold | $0 | $0 | $1 | $0 |
| Gross Profit | $4 | $3 | $3 | $3 |
| % Margin | 89% | 88.6% | 85.2% | 85.8% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Expenses | $3 | $3 | $3 | $2 |
| Operating Income | $1 | $1 | -$0 | $0 |
| % Margin | 17.6% | 15.1% | -1.8% | 5.5% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | -$0 | -$0 |
| Tax Expense | -$0 | -$0 | -$0 | $0 |
| Net Income | $1 | $0 | -$0 | -$0 |
| % Margin | 13.8% | 10.8% | -6.1% | -10.6% |
| EPS | 9.06 | 6.55 | -3.58 | -5.51 |
| % Growth | 38.3% | 283% | 35% | – |
| EPS Diluted | 8.65 | 6.1 | -3.58 | -5.51 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $2 | $1 | $1 | $1 |
| % Margin | 37.4% | 37.8% | 40.1% | 33.2% |